Designing Late Phase Clinical Trials of Disease-modifying Agents to Delay or Prevent Dementia due to Alzheimer’s Disease

This document reports on a project conducted by the Center for Medical Technology Policy’s Green Park Collaborative to create multi-stakeholder vetted recommendations for the design of studies in later phases of drug development to evaluate the ability of disease-modifying agents to delay or prevent the onset of dementia due to Alzheimer’s disease.